Kolon Life Science, Inc.

Kolon Tissuegene, Inc.

Heonsik Choi

Sujeong Kim

Minjung Kim

Minju Kim

Daewook Kim

Kyoungbaek Choi

Hyeonyoul Lee

Min Soo Kim

Hyesun Lee

Jangjoon Park

Jongho Cho

Min Kim

Joonsung Kim

Hwanjun Choi

Eunjin Lee

Jieun Hong

Soondong Lee

Jaeil Shin

Yeomoon Sim

Yejin Kwon

Haesu Kang

The present invention relates to a recombinant vaccinia virus in which the expression of some genes is inhibited, and a use thereof. The recombinant vaccinia virus of the present invention selectively kills cancer cells, and has an excellent reproducibility in cancer cells. Also, the virus has a lower toxicity to normal cells, and thus has an advantage of being safe for a human body. Therefore, the recombinant vaccinia virus of the present invention can be effectively used as a composition for treating cancer.

Recombinant vaccinia virus and use thereof

The present invention relates to: a composition for alleviating or treating pain, the composition comprising glutamate decarboxylase and a gene coding for an anti-inflammatory cytokine; and a method for alleviating or treating pain by using the composition.

Composition for treating pain

Provided is a cell therapeutic agent for treating an inflammatory disease induced by a hyperimmune response, more specifically, a composition for treating an inflammatory disease induced by a hyperimmune response, which comprises (i) a chondrocyte or a cell capable of differentiating into a chondrocyte; and (ii) a cell into which a gene encoding TGF-&#x3b2; is introduced, wherein the cell in (ii) is derived from human embryonic kidney 293 (HEK-293) cell.

Composition for treating inflammatory disease induced by hyperimmune response

A method for delivery of a therapeutic agent to a nervous tissue. In particular, a method of delivering a therapeutic agent to a nervous tissue protected by the brain-blood barrier or meninges is disclosed. The method for delivery allows delivery of a therapeutic agent to a nervous tissue with high efficiency. In addition, the delivery method of a therapeutic agent to a nervous tissue is safe since it has lower side effects such as nervous damage than a method of administering a therapeutic agent directly to a nervous tissue.

Method for delivery of biological molecule to nervous tissue

Growing community of inventors

Seoul, South Korea

Heonsik Choi